NEW YORK (GenomeWeb News) – Navigenics has reeled in $18 million in Series C financing from an investment round that included The Procter and Gamble Company, Kleiner Perkins Caufield and Byers, and Mohr Davidow Ventures.

The company plans to use the financing to continue researching ways genomics can be used in preventive health care and to "expand our clinical offerings into exciting new areas and lead the way in making personal genomics an integral part of employer-sponsored preventive health and wellness programs," Navigenics CEO and President Vance Vanier said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.